- Home
- CRIS vs ANTX Comparison
CRIS vs ANTX Comparison
Compare CRIS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- ANTX
- Stock Information
- Founded
- CRIS 2000
- ANTX 2017
- Country
- CRIS United States
- ANTX United States
- Employees
- CRIS N/A
- ANTX N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- ANTX Health Care
- Exchange
- CRIS Nasdaq
- ANTX Nasdaq
- Market Cap
- CRIS 32.8M
- ANTX 37.6M
- IPO Year
- CRIS 2000
- ANTX 2022
- Fundamental
- Price
- CRIS $3.29
- ANTX $1.27
- Analyst Decision
- CRIS Strong Buy
- ANTX Hold
- Analyst Count
- CRIS 3
- ANTX 5
- Target Price
- CRIS $23.00
- ANTX $3.50
- AVG Volume (30 Days)
- CRIS 243.3K
- ANTX 143.7K
- Earning Date
- CRIS 02-06-2025
- ANTX 11-13-2024
- Dividend Yield
- CRIS N/A
- ANTX N/A
- EPS Growth
- CRIS N/A
- ANTX N/A
- EPS
- CRIS N/A
- ANTX N/A
- Revenue
- CRIS $10,259,000.00
- ANTX N/A
- Revenue This Year
- CRIS N/A
- ANTX N/A
- Revenue Next Year
- CRIS N/A
- ANTX N/A
- P/E Ratio
- CRIS N/A
- ANTX N/A
- Revenue Growth
- CRIS 0.44
- ANTX N/A
- 52 Week Low
- CRIS $2.86
- ANTX $0.87
- 52 Week High
- CRIS $17.49
- ANTX $21.40
- Technical
- Relative Strength Index (RSI)
- CRIS 44.97
- ANTX 44.51
- Support Level
- CRIS $3.10
- ANTX $1.34
- Resistance Level
- CRIS $3.60
- ANTX $1.28
- Average True Range (ATR)
- CRIS 0.37
- ANTX 0.06
- MACD
- CRIS 0.00
- ANTX -0.02
- Stochastic Oscillator
- CRIS 26.22
- ANTX 21.74
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.